invitrolize, a company focused on advanced in vitro models, has secured $2.8M in Seed funding.
The startup's core offering is an in vitro model that allows for the identification and differentiation of respiratory sensitizers and respiratory irritants. This technology is notable for being the first to achieve this crucial distinction under air-liquid interphase realistic exposure conditions, providing a new level of precision in assessing potential respiratory hazards.













